Corbus Pharmaceuticals Holdings, Inc. - Common Stock (CRBP)

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company's diversified pipeline.

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over weight loss results.